Vogt-koyanagi-harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma

Journal of Immunotherapy

Volumn 38, Issue 2, 2015, Pages 80-84

  Crosson, Jason N ^a   Laird, Philip W ^a   Debiec, Matthew ^a   Bergstrom, Chris S ^a   Lawson, David H ^a   Yeh, Steven ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmunity; CTLA 4 antibody; immunotherapy; ipilimumab; melanoma; uveitis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA A2 ANTIGEN; IPILIMUMAB; MELANOMA ANTIGEN; AUTOANTIGEN; HLA-A*02:01 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; CELL SURVIVAL; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOLOGICAL TOLERANCE; METASTATIC MELANOMA; MIDDLE AGED; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VOGT KOYANAGI SYNDROME; CHEMICALLY INDUCED; IMMUNOLOGY; IMMUNOTHERAPY; MELANOCYTE; MELANOMA; METABOLISM; METASTASIS; SKIN NEOPLASMS; T LYMPHOCYTE; UVEOMENINGOENCEPHALITIC SYNDROME;

ANTIBODIES, MONOCLONAL; AUTOANTIGENS; AUTOIMMUNITY; CTLA-4 ANTIGEN; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; T-LYMPHOCYTES; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 84922698461     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000066     Document Type: Article

References (19)

1. Neuman HB, Patel A, Hanlon C, et al. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14:2847-2853.
2. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
3. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med. 2004;350:1461-1463.
4. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
5. Wolchok JD, Hodi SF, Weber JD, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1-13.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
7. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652.
8. Robinson MR, Chi-Chao C, Yang CJ, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. J Immunother. 2014;27:478-479.
9. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)- induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin Cases Brief Rep. 2012;6:423-426.
10. Yervoy s (Ipilimumab) [package insert]. New York, NY: Bristol-Myers Squibb; 2011.
11. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053.
12. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011;17:896-906.
13. Lutzky J, Wolchok J, Hamid O, et al. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(15S): abstract 9034.
14. Yeh S, Karne NK, Kerkar SP, et al. Ocular and systemic autoimmunity following successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009;116:981-989.
15. Dudley ME, Wunderlich JR, Yang JC, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:136-139.
16. Sugita S, Takase H, Taguchi C, et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci. 2006;47:2547-2554.
17. Sugita S, Sagawa K, Mochizuki M, et al. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol. 1996;8:799-803.
18. Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9.
19. Davis JL, Mittal KK, Freidlin V, et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology. 1990;97:1137-1142.